Tvardi Therapeutics Inc. (NASDAQ: TVRD) announced that its Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis did ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE